Comparative Pharmacology
Head-to-head clinical analysis: AURYXIA versus CALCIBIND.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AURYXIA versus CALCIBIND.
AURYXIA vs CALCIBIND
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
AURYXIA (ferric citrate) is a phosphate binder that reduces serum phosphate by binding dietary phosphate in the gastrointestinal tract, forming insoluble ferric phosphate complexes that are excreted in the feces. The iron component also increases serum iron parameters and may improve iron stores.
CALCIBIND (sodium polystyrene sulfonate) is a cation-exchange resin that exchanges sodium ions for potassium ions in the gastrointestinal tract, primarily in the colon, thereby reducing serum potassium levels.
Adult: 1 tablet (1700 mg ferric citrate) three times daily with meals, titrated every 2-4 weeks to achieve target serum phosphate levels. Maximum dose: 12 tablets per day.
5 mg orally once daily, taken without food or with a low-fat meal.
None Documented
None Documented
Not applicable; systemic absorption is minimal. AURYXIA is not absorbed and acts locally in the GI tract.
Terminal elimination half-life: 2-4 hours in patients with normal renal function; prolonged to 12-24 hours in severe renal impairment (eGFR <30 mL/min), necessitating dose adjustment.
Primarily fecal as unabsorbed drug (≥99%). Renal excretion is negligible (<1%).
Primarily renal (90% as unchanged drug via glomerular filtration and tubular secretion). Biliary/fecal: 10% (unabsorbed drug and metabolites).
Category C
Category C
Phosphate Binder
Phosphate Binder